A statement released earlier today by Citigroup about Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) bumps the target price to $155.00
- Updated: September 19, 2016
Citigroup bumped the target price of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to $155, reporting a possible upside of 0.18%.
On Friday September 16 2016, FBR & Co. released a statement about Alexion Pharmaceuticals Inc.(NASDAQ:ALXN) bumped the target price from $82.00 to $92.00 that suggested a downside of -0.29%.
Just yesterday Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded 0.00% even at $131.18. ALXN’s 50-day average is $131.30 and its 200-day average is $135.95. The last close is down 3.51% from the two hundred day moving average, compared to the S&P 500 Index which has decreased -0.01% over the same time. Trade volume was down over the average, with 0 shares of ALXN changing hands under the typical 1,817,640 shares..
See Graph Below:
With a market capitalization of $0.0, Alexion Pharmaceuticals Inc. has a one-year low of $110.56 and a one-year high of $193.45 with a PE ratio of 330.
In addition to Citigroup reporting it’s target price, a total of 18 equity analysts have issued a report on ALXN. The average target price is $187.61 with seven analysts rating the company a strong buy, six firms rating the company a buy, seven analyts rating the stock a hold, 0 rating the stock to underperform, and finally 0 firmsrating the stock as sell.
General Company Details For Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), and a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.